Estrogen receptor profiles: Changes in mouse and rat mammary tumors by treatment with selective estrogen receptor modifiers

Medical Principles and Practice

Volumn 13, Issue 4, 2004, Pages 220-226

  Actis, A M ^a   Cocca, C M ^a   Gutierrez, A ^a   Croci, M ^b   Rivera, E S ^a   Bergoc, R M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Instituto de Inmunooncología Crescenti   (Argentina)

Author keywords

Estrogen receptor conformers; Estrogen receptor isoforms; Mammary tumors, mouse; Mammary tumors, rats; Raloxifene; Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; METHYLNITROSOUREA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER HORMONE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL NEOPLASM; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; RAT; RECEPTOR UPREGULATION; TUMOR GROWTH;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; MICE; MICE, INBRED BALB C; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN CONFORMATION; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 3042640749     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078320     Document Type: Article

References (30)

1. Peterson CM: Estrogen and progesterone receptors: An overview from the year 2000. Mol Endocrinol 2000;14:382-392.
2. Foster JS, Henley DC, Bulowsky A, Seth P, Wimalasena J: Multifaceted regulation of cell cycle progression by estrogen: Regulation of Cdk inhibitors and Cdc25A independent of cyclin Di-Cdk4 function. Mol Cell Biol 2001;21:794-810.
3. De Cupis A, Schettini G, Favonmi RE: New vs. old-fashioned oestradiol antagonists in mammary carcinoma: 'In vitro' and 'in vivo' pharmacological approaches. Pharmacol Res 1999; 39:335-344.
4. Tonetti DA, Jordan VC: The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer: J Steroid Biochem Mol Biol 1997;62:119-128.
5. Hopp TA, Fuqua SA: Estrogen receptor variants. J Mammary Gland Biol Neoplasia 1998;3:73-83.
6. Wittliff JL, Allegra J, Day TJ, Hyder SM: Structural features and clinical significance of estrogen receptors; in Moudgil VK (eds): Steroid Receptors in Health and Disease. New York, Plenum Press, 1988, pp 287-312.
7. Puddefoot JR, Baker VA, Bakkers B, Marsigliante S, Barker S, Panahy C, Goode AW, Carpenter R, Vinson GP: The nature and significance of multiple isoforms of the oestrogen receptor in breast tumors. J Mol Endocrinol 1993;11:83-90.
8. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.
9. Moore JT, McKee DD, Slentz-Kesler K, Moore L, Jones SA, Horne EL, Su J, Kliewer SA, Lehmann JM, Willson TM: Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 1998;247:75-78.
10. Baker VA, Puddefoot JR, Marsigliante S, Barker S, Goode AW, Vinson GP: Oestrogen receptor isoforms, their distribution and relation to progesterone receptor levels in breast cancer samples. Br J Cancer 1992;66:1083-1087.
11. Hyder SM, Wiekle RD, Brandt DW: High-performance hydrophobic-interaction chromatography of steroid hormone receptors. J Chromatogr 1985;327:237-246.
12. Jozan S, Julia AM, Carretil A, Eche N, Maisongrosse V, Fouet B, Marques B, David JF: 65 and 47 kDa forms of estrogen receptors in human breast cancer: Relation with estrogen responsiveness. Breast Cancer Res Treat 1991;19:103-109.
13. Faye JC, Toulas C, Bayard F: Differential estrogenic responsiveness of MCF-7 cells. Relationship to the presence of two different estrogen receptors. J Recept Res 1989;9:203-219.
14. Moncharmont B, Ramp G, De Goeij CC, Sluyser M: Comparison of estrogen receptors in hormone-dependent and hormone-independent Grunter strain mouse mammary tumors. Cancer Res 1991;51:3843-3848.
15. Jordan CV: Tamoxifen for the Treatment and Prevention of Breast Cancer. Melville/NY, Northwestern University Medical School, 1999.
16. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe LJ: A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000;6:212-224.
17. Lanari C, Molinolo AA, Pasqualini CD: Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett 1986;33:215-223.
18. Kordon E, Lanari C, Meiss R, Elizalde P, Charreau E, Dosne Pasqualini C: Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res Treat 1990;17:33-43.
19. Actis AM, Caruso SP, Levin E: Estrogen receptor isoforms and progestin hormone dependence in a mouse mammary tumor model. Int J Cancer 1994;58:668-671.
20. Rivera E, Melito G, Davio C, Cricco G, Martín G, Mohamad N, Andrade N, Caro R, Bergoc R: Histopathology and influence of the estral cycle on NMU-induced tumors in rats. Cancer Lett 1994;86:223-228.
21. Martín G, Melito G, Rivera E, Levin E, Davio C, Cricco G, Caro R, Bergoc R: Effect of tamoxifen on intraperitoneal N-nitroso-Nmethylurea induced tumors. Cancer Lett 1996;100:227-234.
22. Martín G, Melito G, Rivera E, Levin E, Davio C, Cricco G, Caro R, Bergoc R: Receptors characterization of intraperitoneally N-nitroso-Nmethylurea- induced mammary tumors in rats. Cancer Lett 1996;101:1-8.
23. Martin G, Davio C, Rivera E, Melito G, Cricco G, Andrade N, Caro R, Bergoc R: Hormone dependence of mammary tumors induced in rats by intraperitoneal NMU injection. Cancer Invest 1997;15:8-17.
24. Actis AM, Dorfman VB, Caruso SP, Levin E: Effects on mouse uterus of three antitumoral drugs acting upon estrogen and progesterone receptors directly and through other transductional pathways. Biochem Pharmacol 1998;55:273-278.
25. Winer B, Brown D, Michels K: Statistical Principles in Experimental Design. New York, McGraw-Hill, 1991.
26. Levenson AS, Jordan VC: The key to the antiestrogenic mechanism of raloxifen is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 1998;56:1872-1875.
27. Levin E, Actis AM, Caruso S, Gass H, Romero R, Qualeta N, Levin RW: Evaluation of a displacement assay with tamoxifen as prognostic indicator in breast-cancer patients with estrogen-receptor-positive tumors. Int J Cancer 1997;73:486-491.
28. Levin E, Levin RW, Qualeta N, Gass H, Romero R, Caruso S, Actis AM: Functional differences in estrogen receptor isoforms of breast tumors. Proc XVIth International Cancer Congress, 1994, vol 1, 161-162.
29. Actis AM, Rilo C, Cocca C, Rivera E, Bergoc R: Opposed effects in treatments with different SERMs in a mouse mammary tumor model. Cancer Detect Prevent 2000;24:S255-S256.
30. Maaronfi Y, Lacroix M, Lespagnard L, Journe F, Larsimont D, Leclerq G: Estrogen receptor of primary breast cancer evidence for intracellular proteolysis. Breast Cancer Res 2000;2:444-454.